Impact of disruptions and recovery for established cervical screening programs across a range of high-income country program designs, using COVID-19 as an example: A modelled analysis
Megan A. Smith, Emily A. Burger, Alejandra Castañón, Inge M.C.M. de Kok, Sharon J. B. Hanley, Matejka Rebolj, Michaela Hall, Erik E. L. Jansen, James Killen, Xavier O'Farrell, Jane J. Kim, Karen Canfell
Topics & Concepts
MedicineColposcopyCervical cancerCervical screeningCervical cancer screeningPap testCoronavirus disease 2019 (COVID-19)PandemicEnvironmental healthCancerFamily medicinePathologyInternal medicineDiseaseInfectious disease (medical specialty)Cervical Cancer and HPV ResearchCOVID-19 and healthcare impactsGlobal Cancer Incidence and Screening